Patents by Inventor Jose Cancelas

Jose Cancelas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230129271
    Abstract: A small molecule compound IODVA1 has been found to have cellular inhibitory activity against several transformed cell lines including Ras-driven cells. IODVA1 decreases cell-cell and cell-extra cellular matrix interactions and reduces growth of Ras-driven tumors. Applicants also synthesized compound NIRA2 and showed in vitro and in vivo efficacy and potency against models of Ph+(BCR-ABL1) B-ALL and of colon adenocarcinoma xenografts.
    Type: Application
    Filed: December 13, 2022
    Publication date: April 27, 2023
    Inventors: Nicolas Nassar, William Seibel, Anjelika Gasilina, Jose Cancelas
  • Publication number: 20230086683
    Abstract: Disclosed are compounds and compositions for slowing, preventing, or reversing platelet damage, particularly as may occur during blood banking or during refrigeration of platelets. Also disclosed herein are methods for storing platelets and methods for improving platelet survival upon transfusion with one or more compounds or compositions as described herein.
    Type: Application
    Filed: January 13, 2021
    Publication date: March 23, 2023
    Inventors: Yi Zheng, Jose Cancelas
  • Publication number: 20230068990
    Abstract: Disclosed are compounds and compositions for slowing, preventing, or reversing platelet damage, particularly as may occur during blood banking or during refrigeration of platelets. Also disclosed herein are methods for storing platelets and methods for improving platelet survival upon transfusion with one or more compounds or compositions as described herein.
    Type: Application
    Filed: January 13, 2021
    Publication date: March 2, 2023
    Inventors: Yi Zheng, Jose Cancelas
  • Patent number: 11564913
    Abstract: A small molecule compound IODVA1 has been found to have cellular inhibitory activity against several transformed cell lines including Ras-driven cells. IODVA1 decreases cell-cell and cell-extra cellular matrix interactions and reduces growth of Ras-driven tumors. Applicants also synthesized compound NIRA2 and showed in vitro and in vivo efficacy and potency against models of Ph+(BCR-ABL1) B-ALL and of colon adenocarcinoma xenografts.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: January 31, 2023
    Assignee: Children's Hospital Medical Center
    Inventors: Nicolas Nassar, William Seibel, Anjelika Gasilina, Jose Cancelas
  • Publication number: 20220061312
    Abstract: Disclosed are compositions and methods for slowing, preventing, or reversing platelet damage, particularly as may occur during blood banking or during refrigeration of platelets. The composition may include one or more of a RAC inhibitor, a CDC42 inhibitor, a RHOA inhibitor, or a combination thereof. The compositions may further include a pharmaceutically acceptable carrier.
    Type: Application
    Filed: November 12, 2021
    Publication date: March 3, 2022
    Inventors: Yi Zheng, Jose Cancelas
  • Patent number: 11172673
    Abstract: Disclosed are compositions and methods for slowing, preventing, or reversing platelet damage, particularly as may occur during blood banking or during refrigeration of platelets. The composition may include one or more of a RAC inhibitor, a CDC42 inhibitor, a RHOA inhibitor, or a combination thereof. The compositions may further include a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: November 16, 2021
    Assignees: CHILDREN'S HOSPITAL MEDICAL CENTER, UNIVERSITY OF CINCINNATI
    Inventors: Yi Zheng, Jose Cancelas
  • Publication number: 20200345712
    Abstract: A small molecule compound IODVA1 has been found to have cellular inhibitory activity against several transformed cell lines including Ras-driven cells. IODVA1 decreases cell-cell and cell-extra cellular matrix interactions and reduces growth of Ras-driven tumors. Applicants also synthesized compound NIRA2 and showed in vitro and in vivo efficacy and potency against models of Ph+(BCR-ABL1) B-ALL and of colon adenocarcinoma xenografts.
    Type: Application
    Filed: May 1, 2020
    Publication date: November 5, 2020
    Inventors: Nicolas Nassar, William Seibel, Anjelika Gasilina, Jose Cancelas
  • Patent number: 10405538
    Abstract: Disclosed are compositions and methods for slowing, preventing, or reversing platelet damage, particularly as may occur during blood banking or during refrigeration of platelets. The composition may include one or more of a RAC inhibitor, a CDC42 inhibitor, a RHOA inhibitor, or a combination thereof. The compositions may further include a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: September 10, 2019
    Assignees: CHILDREN'S HOSPITAL MEDICAL CENTER, UNIVERSITY OF CINCINNATI
    Inventors: Yi Zheng, Jose Cancelas
  • Publication number: 20190021307
    Abstract: Disclosed are compositions and methods for slowing, preventing, or reversing platelet damage, particularly as may occur during blood banking or during refrigeration of platelets. The composition may include one or more of a RAC inhibitor, a CDC42 inhibitor, a RHOA inhibitor, or a combination thereof. The compositions may further include a pharmaceutically acceptable carrier.
    Type: Application
    Filed: July 20, 2018
    Publication date: January 24, 2019
    Inventors: Yi Zheng, Jose Cancelas
  • Patent number: 10028503
    Abstract: Disclosed are compositions and methods for slowing, preventing, or reversing platelet damage, particularly as may occur during blood banking or during refrigeration of platelets. The composition may include one or more of a RAC inhibitor, a CDC42 inhibitor, a RHOA inhibitor, or a combination thereof. The compositions may further include a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: July 24, 2018
    Assignee: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Yi Zheng, Jose Cancelas
  • Publication number: 20180139952
    Abstract: Disclosed are compositions and methods for slowing, preventing, or reversing platelet damage, particularly as may occur during blood banking or during refrigeration of platelets. The composition may include one or more of a RAC inhibitor, a CDC42 inhibitor, a RHOA inhibitor, or a combination thereof. The compositions may further include a pharmaceutically acceptable carrier.
    Type: Application
    Filed: January 18, 2018
    Publication date: May 24, 2018
    Inventors: Yi Zheng, Jose Cancelas
  • Publication number: 20150366182
    Abstract: Disclosed are compositions and methods for slowing, preventing, or reversing platelet damage, particularly as may occur during blood banking or during refrigeration of platelets. The composition may include one or more of a RAC inhibitor, a CDC42 inhibitor, a RHOA inhibitor, or a combination thereof. The compositions may further include a pharmaceutically acceptable carrier.
    Type: Application
    Filed: June 18, 2015
    Publication date: December 24, 2015
    Inventors: Yi Zheng, Jose Cancelas